Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Accumulated Expenses: 2024-2025

Historic Accumulated Expenses for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $14.6 million.

  • Kura Oncology's Accumulated Expenses rose 16.93% to $14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.6 million, marking a year-over-year increase of 16.93%. This contributed to the annual value of $17.5 million for FY2024, which is N/A change from last year.
  • Per Kura Oncology's latest filing, its Accumulated Expenses stood at $14.6 million for Q3 2025, which was up 45.53% from $10.0 million recorded in Q2 2025.
  • Kura Oncology's Accumulated Expenses' 5-year high stood at $17.5 million during Q4 2024, with a 5-year trough of $6.1 million in Q1 2024.
  • For the 2-year period, Kura Oncology's Accumulated Expenses averaged around $11.0 million, with its median value being $10.0 million (2025).
  • Data for Kura Oncology's Accumulated Expenses shows a peak YoY rose of 18.41% (in 2025) over the last 5 years.
  • Over the past 2 years, Kura Oncology's Accumulated Expenses (Quarterly) stood at $17.5 million in 2024, then rose by 16.93% to $14.6 million in 2025.
  • Its Accumulated Expenses was $14.6 million in Q3 2025, compared to $10.0 million in Q2 2025 and $7.2 million in Q1 2025.